Abstract library

38 results for "Mule".
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#2797 Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review
Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Dr Persefoni Ioannou
#2881 Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma
Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Jian-An Bai
Authors: Bai J A, Tang Q, ...
#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs
Introduction: NETs overexpress somatostatin receptors (SSTRs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives
#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma
Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#3084 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Case Report and Review of Literature
Introduction: Majority of euroendocrine tumorsare found in the gastrointestinal tract and bronchopulmonary. Multifocal disease is common among patients with low-grade NET. One example of this is diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. DIPNECH is an extremely rare but indolent disease with predilection for nonsmoking, middle-aged women.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mary Anne Cruz
Authors: Cruz M A, ...
#37 Gastric GIST with synchronous neuroendocrine tumor of the pancreas, Case Report and Literature Review
Introduction: The Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These are rare tumors with an incidence of 15 new cases per million per year. They often occur in individuals over the age of 40 years, without gender predominance. The clinical behavior is variable and benign tumors are the most common. They can develop anywhere in the GI tract, but are more frequent in the stomach and small intestine. The primary treatment, when located, is the surgical resection, which can be complemented with the use of imatinib.
The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. They have a slight predominance in males, and are more frequent in the 6th decade of life. Nonfunctioning tumors of islet cells are virtually all malignant tumors, and the treatment consists of surgical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dra Amelia B Tavares
#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#84 Rare association between pancreatic insulinoma and Graves's disease: fortune or misfortune?
Introduction: In spite of low frequency ( 4 cases in 1 million population), insulimoma is a significant pathology because hypoglycemia causes severe neurologic lesions and death.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Carmen Barbu
Authors: Barbu C, Stefan C, Miron A, Giulea C, ...